MedPath
HSA Approval

LEVETIRACETAM VIATRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML

SIN16930P

LEVETIRACETAM VIATRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML

LEVETIRACETAM VIATRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML

January 16, 2024

MYLAN PHARMACEUTICALS PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantMYLAN PHARMACEUTICALS PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INFUSION, SOLUTION CONCENTRATE

INTRAVENOUS

Medical Information

N03AX14

levetiracetam

Manufacturer Information

mylan pharmaceuticals pte. ltd.

Mylan Laboratories Ltd Hosur Steriles Facility (HSF)

Active Ingredients

Levetiracetam

100 mg/ml

Levetiracetam

Documents

Package Inserts

Levetiracetam Viatris Conc for Soln for Inf 100mg per ml package insert.pdf

Approved: January 16, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

LEVETIRACETAM VIATRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML - HSA Approval | MedPath